Wow,what was Bob smoking (2), $24 million loss!!!

Well the leader sounded shady and nervous as usual but was excited and a little smug. Stan sounded like he needed a drink. The good news, our 100 year old innovative drug (morphine) got a small boost from the FDA who look like they'll approve the Arymo formulation (that's not a great surprise given Teva's leadership position in the space). The continuing bad news - sales were 30% behind expectations at only $3.5 million for the quarter - so much for $20 million for the year. Losses rose to nearly $24 million for the quarter, or $42 million year to date, (we'll be around $100 million by the year end)......shares have gone up a little from a very low base but are still 40% down on a year ago. thestreet.com rates us at D-

• Net Loss: Net loss for the quarter ended June 30, 2016 was $23.8 million, or $0.97 per share, compared to a net loss of $17.1 million, or $1.03 per share, for the quarter ended June 30, 2015.

 

Well, that explains Tim's departure. Deanna Q1, Tim Q2. Who will #BullshitBob and MS blame in the next?

 

Hi all, as a lowly Territory Manager I know that I'm taking a risk posting here but I've been told that it's not traceable. So here goes. I'm not a lofty exec but really love my job because I meet interesting and passionate people in healthcare and I think that ultimately we could make a difference. I've been involved with the healthcare industry all my working life and this is my latest in a number of professional Pharmaceutical Rep positions. It's the first with a company at this early stage.

So its common knowledge that Sprix and Oxyado haven't hit the numbers that we hoped for and are failing but Sales Management's explanation is that this is 'the practice before the home run - Arymo'. Obviously the FDA news this week is good news - I think. We should be on for a Fall launch. So I have two questions:

1. How long can a business like ours make huge losses before it becomes bankrupt? (and I lose my job)
2. Given our lack luster performance with Sprix and Oxyado (both old drugs with a formulation difference), how successful will we be with Arymo, which is just morphine with a formulation difference?

I really am anxious, morale here is low and chatter among me and other TMs is that we're on the road to no where.

 

Every company is different as far as the breaking point where the financial losses lead to bankruptcy; it often depends on whether or not investors are willing to continue to inject funds into a company that's hemorrhaging money. Egalet probably has enough reserves to stave off financial collapse for a year, or so.
It is also very difficult to predict how well Arymo will perform. Maybe docs will embrace it, and it will exceed all expectations -unlikely, but possible. I think a more realistic scenario is your docs will reject this, and any other product Egalet produces, because they will forever associate Egalet with the laughably bad products of Oxyado and Sprix. Considering first impressions often determine someone's overall perception of you, Egalet's first two impressions -Sprix & Oxyado, have branded them a fraud. I believe you should look for other opportunities outside of the pain management market as well, because now -unfortunately, you are looked at as the Rep peddling bogus pain products.

 

Thanks for the explanation and advice although I still don't know how a business can make a $100 million loss and still stay viable.

I called a couple of recruiters and they both said "Egalet, how do we explain that mistake on your resume?" (Paraphrase). Definitely it's a problem. Not sure if I should just wait for Arymo. As nobody is getting TRx for Sprix or Oxyado it's quite easy to slack off and not get noticed for a couple of months. That's what I'll do, at least it's a pay check.

 

How many scripts for President's Circle?

 

Two or three.......

 

So,no one is getting President Club, then...

 

Cruisin' the boards and came across this. I live in Wayne, PA so I've heard of this lot. Are they really that bad? Like there's over 5000 views of another thread. That spells trouble.

Seems a bit of micro niche product. So someone had to be on opioid Rx>and opioid abuser>recommended for continued treatment>Rx for Arymo? (that's the new one, right?). What a stupid hassle. So that's like .000000001% of the population.

What's stopping folks (junkies/abusers/bored house wives) just buying an prescription Oxycotin on Market St. or downtown Norristown for $5 a pill??

 

Our stock is going the same way of the Trump black vote......

 

Hey Lindsay Mc. How are you doing!!? Philly treating you well? We're doing so well in TX. You should have gone with Pfizer...really pro outfit. Cyas!

 

We are done............maybe 1.5 years of capital left, a leadership that is in so far over their heads that they will take that capital and make it work maybe 1 year tops. They have a churn and burn strategy. They have no real plan, they are in panic mode. Just think about the turn over that we have experienced at every level. This is a dysfunctional leadership team and the sales force will be the first to be blamed......well we have been already. Get out as soon as you can. Everyone is being looked at. You have zero worth to management, you have about 3 months,if you are territory is not showing some growth you will be removed and replaced.

 

Did they mention that Pfizer already has Embeda on the market?
I know that they are fat and lazy but not a good sign...

 

Lol, we announce a review of Arymo and Oxyado at Pain Week and our Stock drops like a stone. Nice one upper management and #BullshitBob!!

WAYNE, Pa., Aug. 25, 2016 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions today announced that researchers will present scientific data at PAINWeek 2016 onSeptember 8 in Las Vegas. Four presentations will be on abuse-deterrent product candidate ARYMO™ ER (morphine sulfate) Extended-Release Tablets; one presentation will address abuse-deterrent properties of Egalet's proprietary Guardian ™ Technology; and one presentation will be on marketed product OXAYDO ® (oxycodone HCl, USP) tablets CII.

 

Hi fellow Eagles! Just finishing up my administration after another dull week of trying to detail Sprix/Oxyado. Saw this post about Pain Week. Every week is Pain Week here at Egalet. Haha!! Arymo launch set for October. Dallas and NJ!! See you there.

Free morphine product to chew while we listen to upper management presentations.

 

So I don't understand this. We get the OK for our new product, Arymo, from the FDA and our stock is still 25% less than a year ago. The Street.com rates us as D- and Zacks a 4, sell (only a 5 rating is worse). Does Wall Street and do investors generally know what they're doing???

 

Hey all, Collegium seems a good place to jump ship to. Means we can use our training and experience from here to good effect. I've heard good things about their management. They are looking at a sales team of at least 120. They're actively recruiting. Anyone know them and what they're like to work for?

Check this out.

"The second quarter of 2016 marked an important milestone for Collegium as we transitioned from a development stage company to a commercial pharmaceutical company. Following the FDA approval of our lead product, we announced the commercial launch of Xtampza ® ER and our sales force is now fully engaged in promoting the product to our target physicians," stated Michael Heffernan, Collegium's CEO. "Furthermore, we continue to build our product pipeline through the advancement of our Hydrocodone DETERx ® clinical development program and through the acquisition of the U.S. rights to ONSOLIS ® from BioDelivery Sciences."

• In June 2016, Collegium announced the commercial launch of Xtampza ER. The Xtampza ER commercial launch is supported by a field sales force of approximately 120 retail sales professionals with a primary focus on pain specialists. In addition, an institutional focused sales force of specialty sales representatives is targeting hospitals and long term care facilities.

 

ok boys and girls, previous Egalet alum here. What's the news going on at Egalet? Did I make a good choice in leaving? Will Arymo be the new Viagra of the Pain World? Is Bob still chubby? How much longer can Egalet bleed money before I start to question whether they have connections with Putin.

 

Status quo as you stated. You sound like I met you in NJ at the training session for Oxyado and Sprix. B is still fat and bald......

 

I, too, left Egalet back in December of 2015; 3 weeks after training in New Jersey. I can honestly tell you we made the correct choice. Egalet is an absolute dumpster fire, and it's products are laughably bad.